ImmunityBio, Inc.
$8.01
▼
-1.17%
2026-04-22 10:12:13
immunitybio.com
NMS: IBRX
Explore ImmunityBio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.28 B
Current Price
$8.01
52W High / Low
$12.43 / $1.83
Stock P/E
—
Book Value
$-0.49
Dividend Yield
—
ROCE
-58.17%
ROE
71.02%
Face Value
—
EPS
$-0.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
684
Beta
0.06
Debt / Equity
-1.04
Current Ratio
5.1
Quick Ratio
5.08
Forward P/E
-364
Price / Sales
66.36
Enterprise Value
$8.09 B
EV / EBITDA
-33.61
EV / Revenue
71.39
Rating
Strong Buy
Target Price
$14.8
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 2. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 3. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 4. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
| 5. | Prime Medicine, Inc. | $3.89 | — | $687.9 M | — | -68.25% | -1.47% | $6.94 / $1.11 | $0.68 |
| 6. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 7. | Kiora Pharmaceuticals, Inc. | $2.52 | — | $9.96 M | — | -45.87% | -51.74% | $4.18 / $1.76 | $4.29 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 38.28 M | 32.06 M | 26.43 M | 16.52 M | 7.55 M | — |
| Operating Profit | -64.68 M | -55.63 M | -71.28 M | -64.43 M | -69.4 M | — |
| Net Profit | -61.94 M | -67.25 M | -92.56 M | -129.65 M | -59.16 M | — |
| EPS in Rs | -0.06 | -0.07 | -0.09 | -0.13 | -0.06 | -0.14 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 113.29 M | 14.74 M | 0.62 M | 0.24 M |
| Operating Profit | -256.03 M | -344.18 M | -361.36 M | -350.62 M |
| Net Profit | -351.4 M | -413.56 M | -583.2 M | -416.57 M |
| EPS in Rs | -0.34 | -0.4 | -0.56 | -0.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 501.9 M | 382.93 M | 504.45 M | 362.36 M |
| Total Liabilities | 1 B | 871.06 M | 1.09 B | 812.18 M |
| Equity | -500.47 M | -489.1 M | -586.99 M | -447.33 M |
| Current Assets | 314.88 M | 184.59 M | 294.08 M | 140.58 M |
| Current Liabilities | 61.75 M | 54.94 M | 58.28 M | 500.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -304.94 M | -391.24 M | -366.76 M | -337.51 M |
| Investing CF | -149.8 M | -12.25 M | -30.47 M | 27.3 M |
| Financing CF | 400.24 M | 281.63 M | 558.34 M | 233.61 M |
| Free CF | -309.19 M | -398.12 M | -397.34 M | -436.9 M |
| Capex | -4.25 M | -6.89 M | -30.58 M | -99.39 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2270.58% | 159.17% | — | — |
| Earnings Growth % | 29.09% | -40% | — | — |
| Profit Margin % | -2804.77% | -93761.41% | -173569.58% | — |
| Operating Margin % | -2334.23% | -58097.11% | -146090.42% | — |
| Gross Margin % | 100% | 100% | 100% | — |
| EBITDA Margin % | -1792.82% | -76941.64% | -146617.08% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.